bortezomib
(Bortezomib)Novadoz Pharmaceuticals LLC
Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Medications for Lymphoma Mantlecell
9 results
bortezomib
(Bortezomib)Accord Healthcare Inc.Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(BORTEZOMIB)Hospira, Inc.Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(bortezomib)Hikma Pharmaceuticals USA Inc.Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(Bortezomib)NorthStar RxLLCUsage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.boruzu
(Bortezomib)Amneal Pharmaceuticals LLCUsage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.lenalidomide
(Lenalidomide)Biocon Pharma Inc.Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.lenalidomide
(lenalidomide)Cipla USA Inc.Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.lenalidomide
(Lenalidomide)Teva Pharmaceuticals IncUsage: Lenalidomide is indicated for adult patients with multiple myeloma in combination with dexamethasone, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes with a deletion 5q abnormality, and relapsed or progressed mantle cell lymphoma after two prior therapies. Not recommended for CLL.